Sulpiride is a new antipsychotic agent chemically different from recognized psychotropic compounds. The animal profile and the rapid urinary excretion without metabolism also distinguishes this drug from other neuroleptics. Previous studies have indicated therapeutic efficacy and few side effects. Sulpiride was evaluated in 10 hospitalized, chronic schizophrenic patients over a 10 week period. The overall findings support those studies reporting neuroleptic activity. Although no side effects were encountered, a mild leukocytosis was observed in one patient and broadening and flattening of T-waves was observed in another when each received high doses. Toxic levels appear to be well beyond the therapeutic range.